Submissions for variant NM_058179.4(PSAT1):c.367A>G (p.Ile123Val)

gnomAD frequency: 0.00213  dbSNP: rs116577685

Total submissions: 5

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Illumina Laboratory Services, Illumina	RCV000304704	SCV000480848	likely benign	PSAT deficiency	2018-01-12	criteria provided, single submitter	clinical testing	This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000652405	SCV000774275	likely benign	Neu-Laxova syndrome 2	2025-02-02	criteria provided, single submitter	clinical testing
Dudley Research Group, Pacific Northwest Research Institute	RCV001254501	SCV001430480	not provided	not provided		no assertion provided	research
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV001254501	SCV001550285	likely benign	not provided		no assertion criteria provided	clinical testing	The PSAT1 p.Ile123Val variant was not identified in the literature nor was it identified in Cosmic or LOVD 3.0. The variant was identified in dbSNP (ID: rs116577685) and ClinVar (classified as likely benign by Illumina and as a VUS by Invitae). The variant was also identified in control databases in 180 of 282824 chromosomes (1 homozygous) at a frequency of 0.000636 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 166 of 24964 chromosomes (freq: 0.00665), Latino in 12 of 35434 chromosomes (freq: 0.000339), Other in 1 of 7224 chromosomes (freq: 0.000138) and European (non-Finnish) in 1 of 129142 chromosomes (freq: 0.000008), while the variant was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), and South Asian populations. The p.Ile123 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.
PreventionGenetics, part of Exact Sciences	RCV004530489	SCV004726543	likely benign	PSAT1-related disorder	2020-09-08	no assertion criteria provided	clinical testing	This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).